Infectious Disorders - Drug Targets

(Formerly Current Drug Targets - Infectious Disorders)

Jean-Marc Sabatier  
Laboratoire ERT 62 'Ingénierie des peptides à visée thérapeutique' 
Université de la Méditerranée
Faculté de Médecine Nord
Boulevard Pierre Dramard
13916 - MARSEILLE, Cedex 20


Influenza Viruses: Basic Biology and Potential Drug Targets

Author(s): Christopher F. Basler

Affiliation: Dept. Microbiology,Box 1124, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029.

Keywords: Amantadine, influenza virus, ion channel, neuraminidase, neuraminidase inhibitor, pandemic, pathogenesis, rimantadine


Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [282 - 293]
Pages: 12
DOI: 10.2174/187152607783018745